Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Univax Biologics Inc.


Robertson, Stephens' Hurwitz also reiterated a "buy" following FDA approval of the Rockville, Md., company's

WinRho SD

virally inactivated immune globulin (see BioCentury Extra, March 28). As a stand-alone asset, WinRho is worth $9-10 a share, making the rest of UNVX's promising pipeline a virtual

Read the full 508 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers